Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.78
Nov 13 • 3:59 PM ET Dollar change-0.15 Percentage change(-5.12%)
Aftermarket Close
2.78
Aftermarket • 7:35 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
26.03M
Enterprise Value
-62.81M
Income
-91.00M
Sales
0.00M
Book/sh
10.97
Cash/sh
10.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
102
IPO
Jan 26, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.25
P/C
0.26
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
6.09
Current Ratio
6.09
Debt/Eq
0.12
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
-8.57
EPS next Y
-4.95
EPS next Q
-1.76
EPS this Y
57.15%
EPS next Y
31.87%
EPS next 5Y
43.96%
EPS past 3/5Y
14.57% 26.71%
Sales past 3/5Y
- -
EPS Y/Y TTM
57.60%
Sales Y/Y TTM
-
EPS Q/Q
62.76%
Sales Q/Q
-
Insider Own
12.22%
Insider Trans
0.00%
Inst Own
52.15%
Inst Trans
3.70%
ROA
-67.55%
ROE
-85.91%
ROIC
-81.28%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-21.13%
SMA50
-53.15%
SMA200
-62.56%
Trades
Shs Outstand
9.36M
Shs Float
8.22M
52W High
11.20 -75.18%
52W Low
2.84 -2.11%
Volatility
8.60% 8.29%
ATR (14)
0.34
RSI (14)
17.54
Beta
1.75
Rel Volume
1.26
Avg Volume
230.46K
Volume
286,428
Perf Week
-8.85%
Perf Month
-45.91%
Perf Quarter
-68.19%
Perf Half Y
-63.80%
Perf YTD
-66.98%
Perf Year
-73.80%
Perf 3Y
-85.28%
Perf 5Y
-98.22%
Perf 10Y
-
Prev Close
2.93
Price
2.78
Change %
-5.12%
Consensus
Strong Buy
Avg. Price Target
$29.00
Implied Upside
+943.2%
Analysts11incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 05, 2026Resumed
JEF logoJJefferies
Buy$19+583.5%
Sep 30, 2024Resumed
GGuggenheim
Buy$7+151.8%
Sep 11, 2024Downgrade
HH.C. Wainwright
Buy → Neutral
Jun 27, 2023Downgrade
JJMP Securities
Mkt Outperform → Mkt Perform
Jun 27, 2023Downgrade
GGuggenheim
Buy → Neutral
Jun 01, 2023Downgrade
JPM logoJJP Morgan
Overweight → Neutral$20 → $6+115.8%
Sep 21, 2022Initiated
JPM logoJJP Morgan
Overweight$23+727.3%
Mar 31, 2022Initiated
SSMBC Nikko
Outperform$28+907.2%
Mar 08, 2022Initiated
TFC logoTTruist
Buy$30+979.1%
Mar 04, 2022Initiated
JEF logoJJefferies
Buy$27+871.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerFeb 20 '26Buy7.2774,751543,4401,182,624Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerFeb 19 '26Buy7.2174,268535,4721,107,873Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerFeb 18 '26Buy7.0474,577525,0221,033,605Apr 13 05:20 PM
ORBIMED ADVISORS LLC10% OwnerApr 08 '26Sale6.4272,939468,0820Apr 09 05:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 07 '26Sale6.5231,719206,76532,523Apr 09 05:38 PM
OrbiMed Genesis Master Fund, LShareholderApr 09 '26Proposed Sale6.5578,499514,168Apr 09 05:34 PM
OrbiMed Israel Partners II, L.ShareholderApr 08 '26Proposed Sale6.5540,416264,725Apr 08 08:14 PM
OrbiMed Israel Partners LimiteShareholderApr 07 '26Proposed Sale6.4364,242413,076Apr 07 08:46 PM
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
C.P.A.Mr. Chen Schor BA
Senior VP & Chief Scientific OfficerDr. Blake Aftab Ph.D.
Ph.D.Dr. Lloyd Klickstein M.D.
Chief Financial OfficerMr. Brian Nicholas Harvey M.B.A.
Chief Technology OfficerDr. Donald Healey Ph.D.